Actively Recruiting
AMH as a Predictor of Infertility Risk in Children With Cancer (CHANCE)
Led by Erasme University Hospital · Updated on 2020-05-04
275
Participants Needed
10
Research Sites
1182 weeks
Total Duration
On this page
Sponsors
E
Erasme University Hospital
Lead Sponsor
Q
Queen Fabiola Children's University Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
While most of the children spontaneously recover menstruation or experienced normal puberty after chemotherapy, their ovarian reserve may be impaired by treatment inducing future infertility. Fertility preservation is currently proposed for selected prepubertal patients with a high risk of premature ovarian failure after treatment (mostly conditioning regimen for bone marrow transplantation). For patients with low or moderate risks, counselling is very difficult and no fertility preservation procedure is usually proposed for these patients as no marker of the ovarian reserve has been validated in this young population to assess the individual risk. The primary objective of the study is to prevent long-term treatment-related infertility by detecting the young patients who normally progressed to menarche but have a reduced ovarian reserve. These patients may benefit from particular follow-up and fertility preservation procedure.
CONDITIONS
Official Title
AMH as a Predictor of Infertility Risk in Children With Cancer (CHANCE)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients aged 3 to 14 years
- Belong to one of these groups: high risk (conditioning therapy for bone marrow transplant or pelvic irradiation), moderate/low risk (treated with chemotherapy regimens with moderate or low risk of ovarian insufficiency), or no risk (chronic benign diseases or malignancies without gonadotoxic treatment)
You will not qualify if you...
- Received central nervous system irradiation or have cerebral tumor
- Current or previous ovarian disease or ovarian surgery
- Family history of premature ovarian failure without surgical or medical cause
- Known severe chronic disease affecting growth or puberty (including malnutrition, anorexia, Turner syndrome, Kallman syndrome, BPES syndrome, uncontrolled diabetes, Cushing syndrome, autoimmune diseases, cystic fibrosis, severe renal dysfunction)
- Genetic or congenital disorders causing mental retardation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 10 locations
1
Centre Hospitalier Chrétien (CHC)- Clinique de l'espérance
Montegnée, Liège, Belgium, 4420
Actively Recruiting
2
Universitair Ziekenhuis Antwerpen
Antwerp, Belgium, 2650
Actively Recruiting
3
Hôpital Universitaire Reine Fabiola (HUDERF)
Brussels, Belgium, 1020
Actively Recruiting
4
Universitair Ziekenhuis Brussels
Brussels, Belgium, 1090
Actively Recruiting
5
UZ-Gent
Ghent, Belgium
Not Yet Recruiting
6
Universitair Ziekenhuis Leuven
Leuven, Belgium, 3000
Actively Recruiting
7
Centre Hospitalier Régional (CHR)-Citadelle
Liège, Belgium, 4000
Actively Recruiting
8
Centre Oscar Lambret
Lille, France, 59000
Actively Recruiting
9
CHRU Lille-Hôpital Jeanne de Flandre
Lille, France, 59037
Actively Recruiting
10
Hôpital Robert Debré
Paris, France
Not Yet Recruiting
Research Team
I
Isabelle Demeestere, PhD
CONTACT
J
Julie Dechene
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here